FDA pulls Covid antibody treatment because it's not effective against dominant omicron variants

By December 3, 2022Business

The FDA said bebtelovimab is no longer authorized for use because it is not expected to neutralize the omicron BQ.1 and BQ.1.1 subvariants.

Spread the love
See also  Citi names its top biotech stock picks for 2023 — and gives one 73% upside

Leave a Reply